|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
198,230,000 |
Market
Cap: |
32.11(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.162 - $0.162 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapies to treat the whole eye. Co.'s gene therapy candidate includes: OCU400, which is used for the treatment of nuclear receptor subfamily 2 group E member 3 mutation-associated retinal diseases and centrosomal protein 290 mutation-associated retinal diseases; OCU410, which is being developed for the treatment of dry age-related macular degeneration (AMD); OCU200, which is designed to treat diabetic macular edema, diabetic retinopathy and wet AMD; and OCU300, which is a small molecule therapeutic in clinical development for patients with ocular graft-versus-host disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
200,278 |
200,278 |
Total Buy Value |
$0 |
$0 |
$99,999 |
$99,999 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
0 |
0 |
0 |
599,809 |
Total Sell Value |
$0 |
$0 |
$0 |
$1,096,737 |
Total People Sold |
0 |
0 |
0 |
3 |
Total Sell Transactions |
0 |
0 |
0 |
8 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kumar Ramesh |
Director |
|
2022-07-18 |
4 |
AS |
$2.57 |
$19,275 |
D/D |
(7,500) |
0 |
|
- |
|
Kumar Ramesh |
Director |
|
2022-07-18 |
4 |
OE |
$0.51 |
$3,825 |
D/D |
7,500 |
7,500 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2022-07-14 |
4 |
AS |
$2.72 |
$408,000 |
D/D |
(150,000) |
752,540 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2022-07-14 |
4 |
OE |
$0.33 |
$49,500 |
D/D |
150,000 |
902,540 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2022-05-13 |
4 |
AS |
$1.92 |
$240,000 |
D/D |
(125,000) |
752,540 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2022-05-13 |
4 |
OE |
$0.33 |
$41,250 |
D/D |
125,000 |
877,540 |
|
- |
|
Kumar Ramesh |
Director |
|
2022-04-18 |
4 |
AS |
$2.83 |
$21,225 |
D/D |
(7,500) |
0 |
|
- |
|
Kumar Ramesh |
Director |
|
2022-04-18 |
4 |
OE |
$0.51 |
$3,825 |
D/D |
7,500 |
7,500 |
|
- |
|
Whittington Marna C |
Director |
|
2022-03-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,000 |
|
- |
|
Crespo Jessica |
CAO/SVP, FinanceOfficer |
|
2022-03-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
17,500 |
|
- |
|
Crespo Jessica |
CAO/SVP, Finance |
|
2022-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
22,940 |
40,440 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2022-03-16 |
4 |
AS |
$2.65 |
$216,831 |
D/D |
(81,823) |
752,540 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2022-03-16 |
4 |
OE |
$0.33 |
$27,002 |
D/D |
81,823 |
834,363 |
|
- |
|
Zhang Junge |
Director |
|
2022-03-03 |
4 |
OE |
$0.51 |
$109,560 |
D/D |
88,000 |
88,000 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2022-02-14 |
4 |
AS |
$3.74 |
$336,600 |
D/D |
(90,000) |
752,540 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2022-02-14 |
4 |
OE |
$0.33 |
$29,700 |
D/D |
90,000 |
842,540 |
|
- |
|
Kumar Ramesh |
Director |
|
2022-01-18 |
4 |
AS |
$4.07 |
$30,525 |
D/D |
(7,500) |
0 |
|
- |
|
Kumar Ramesh |
Director |
|
2022-01-18 |
4 |
OE |
$0.51 |
$3,825 |
D/D |
7,500 |
7,500 |
|
- |
|
Subramanian Sanjay |
Chief Financial Officer |
|
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
125,534 |
161,125 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
346,540 |
752,540 |
|
- |
|
Potti Manish |
Director |
|
2021-12-16 |
4 |
OE |
$0.51 |
$64,530 |
D/D |
45,000 |
45,000 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2021-12-16 |
4 |
AS |
$5.22 |
$600,300 |
I/I |
(115,000) |
1,145,299 |
|
- |
|
Zhang Junge |
Director |
|
2021-11-16 |
4 |
OE |
$2.77 |
$410,878 |
I/I |
145,473 |
876,904 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2021-11-16 |
4 |
AS |
$8.04 |
$924,600 |
I/I |
(115,000) |
1,260,299 |
|
- |
|
Zhang Junge |
Director |
|
2021-11-03 |
4 |
AS |
$17.32 |
$2,603,196 |
I/I |
(150,300) |
731,431 |
|
- |
|
195 Records found
|
|
Page 2 of 8 |
|
|